Tuesday, January 27, 2015
BioCryst Earns Special FDA designation
BioCryst Pharmaceuticals received Fast Track designation for its experimental treatment for hereditary angioedema.
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment